Merck Strikes $6.7B Terns Acquisition to Counter Keytruda Patent Cliff
Key Takeaways
- Merck has agreed to acquire Terns Pharmaceuticals for $6.7 billion, securing a late-stage leukemia candidate to diversify its oncology portfolio.
- The deal provides Merck with TERN-701, a promising treatment for chronic myeloid leukemia, as it prepares for the 2028 patent expiration of its blockbuster drug Keytruda.
Mentioned
Key Intelligence
Key Facts
- 1Merck agreed to acquire Terns Pharmaceuticals for $6.7 billion in an all-cash deal.
- 2The purchase price of $53 per share represents a significant premium for Terns shareholders.
- 3The primary asset in the deal is TERN-701, an allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML).
- 4The acquisition is a strategic move to offset revenue losses from the 2028 patent expiration of Keytruda.
- 5TERN-701 will compete directly with Novartis' Scemblix in the hematology market.
Who's Affected
Analysis
Merck’s $6.7 billion acquisition of Terns Pharmaceuticals represents a decisive move to fortify its oncology pipeline against the looming 'patent cliff' of its top-selling immunotherapy, Keytruda. With Keytruda currently accounting for nearly 40% of Merck’s total revenue, the company is under intense pressure to diversify its portfolio before the drug begins losing patent protection in 2028. The acquisition of Terns, and specifically its lead candidate TERN-701, signals Merck’s intent to become a dominant player in the hematology space, a sector where it has historically had a smaller footprint compared to its solid tumor dominance.
TERN-701 is an oral, allosteric BCR-ABL tyrosine kinase inhibitor (TKI) designed to treat chronic myeloid leukemia (CML). Unlike traditional TKIs that bind to the ATP-binding site of the BCR-ABL protein, allosteric inhibitors like TERN-701 target the myristoyl pocket. This mechanism is intended to offer better specificity and a superior safety profile, potentially overcoming resistance seen with earlier-generation treatments. By acquiring this asset, Merck is positioning itself to compete directly with Novartis, whose drug Scemblix has already validated the commercial potential of the allosteric inhibition approach in the CML market.
Merck’s $6.7 billion acquisition of Terns Pharmaceuticals represents a decisive move to fortify its oncology pipeline against the looming 'patent cliff' of its top-selling immunotherapy, Keytruda.
This deal follows a consistent pattern of strategic M&A for Merck, which has spent billions in recent years to acquire mid-sized biotech firms with late-stage assets. Previous notable deals include the $11.5 billion purchase of Acceleron Pharma and the $10.8 billion acquisition of Prometheus Biosciences. The $53-per-share cash offer for Terns reflects the high premium pharmaceutical giants are willing to pay for de-risked clinical assets that can deliver near-term revenue. For venture capital investors in the biotech space, this exit serves as a benchmark for the valuation of specialized oncology platforms in a consolidating market.
What to Watch
From a market perspective, the acquisition is likely to be viewed as a necessary defensive maneuver. While Keytruda continues to break sales records, the sheer scale of the revenue gap it will leave behind requires multiple 'blockbuster' replacements rather than a single successor. TERN-701, if successful in ongoing trials and subsequent commercialization, provides a high-margin specialty drug that fits Merck’s existing infrastructure. Analysts will be closely watching the integration process and the upcoming clinical data readouts for TERN-701 to determine if the $6.7 billion price tag was a prudent investment in Merck's post-Keytruda future.
Looking forward, the success of this deal hinges on Merck’s ability to navigate the competitive landscape of blood cancers. While TERN-701 shows promise, it enters a field with established players and rapidly evolving standards of care. However, Merck’s massive commercial reach and experience in oncology regulatory filings provide Terns’ technology with a significantly higher probability of reaching global markets than it would have had as a standalone entity. This acquisition likely marks the beginning of a final flurry of deals for Merck as the 2028 deadline approaches.
From the Network
Merck to Acquire Terns for $6.7B to Fortify Oncology Pipeline
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, a strategic move designed to diversify its oncology portfolio. The acquisition comes as Merck prepares
FinanceMerck Acquires Terns for $6.7B to Hedge Against Keytruda Patent Cliff
Merck has agreed to acquire Terns Pharmaceuticals for $6.7 billion in cash to bolster its oncology pipeline ahead of the 2028 patent expiration for its blockbuster drug, Keytruda. The deal centers on
BiotechMerck to Acquire Terns for $6.7B to Mitigate Keytruda Patent Cliff
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion in cash, a strategic move to diversify its oncology pipeline. The deal centers on Terns' promising leuke
How we covered this story
Every story in our startup coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the startup space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled startup-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |